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Abstract 
As pharmacists move toward more patient-centered care through medication therapy management (MTM), important issues and 
conflicts may arise within the therapeutic relationship, requiring pharmacists to use ethical knowledge and skills toward conflict-
resolution.  The purpose of this paper is to explore practical strategies that pharmacists and other champions of MTM may utilize to 
support the ethical principles of autonomy, veracity, nonmaleficence, beneficence, and justice, along with an ethic of care during the 
provision of MTM services.  With a deeper understanding of ethical principles and the Code of Ethics for Pharmacists, pharmacists 
may be more prepared to make difficult ethical decisions, and ultimately, guide better patient care. 
 
 
Introduction 
The role of the pharmacist continues to move towards 
providing direct patient care, such as through provision of 
medication therapy management (MTM).
 1
 While MTM 
encompasses a diverse array of services, the overarching goal 
is to optimize therapeutic outcomes for individual patients.
2
 
One component of MTM is the comprehensive medication 
review and ongoing patient monitoring with personal 
interaction between the pharmacist and patient.  Limited 
information exists regarding the number of pharmacists 
providing comprehensive medication reviews and other MTM 
services; however, one company has reported a network of 
pharmacists exceeding 70,000.
3
  As the number of 
pharmacists providing MTM services continues to grow, care 
should be taken to ensure that the development and 
implementation of MTM programs aligns with key ethical 
principles that form the foundation of The Code of Ethics for 
Pharmacists.
4 
 Codes of ethics are adopted by professions to 
guide ethical decision-making by recognizing what is “right” 
or “wrong”, “good” or “bad” with application of such 
understanding to practice.  Limitations of professional codes 
of ethics include vague guidelines and conflicting principles.  
However, codes of ethics are essential for recognizing the 
values of the profession and lack of adherence to the 
guidelines may even have legal repercussions.  The most cited 
and frequently used principles among ethicists and  
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healthcare providers, since they were first espoused by Tom 
L. Beauchamp and James F. Childress in Principles of 
Biomedical Ethics 1979, include autonomy, nonmaleficence, 
beneficence, and justice.
5
  The Code of Ethics for Pharmacists 
not only focuses on these widely used principles, but also on 
the principle of veracity (honesty and truthfulness).  The 
purpose of this paper is to explore practical strategies that 
pharmacists and other champions of MTM may utilize to 
support the ethical principles of autonomy, veracity, 
nonmaleficence, beneficence, and justice, along with an ethic 
of care. 
 
Ethical Principles 
Autonomy 
Autonomy translates as “self rule” in which the self is free 
from controlling interferences by others or from personal 
limitations that hinder the ability to make choices.  The 
principle of autonomy requires respect for autonomy, which 
may require that one not infringe upon the freedoms of 
others to be self-determining, or may suggest that we 
promote the self-determination of others.  The latter is more 
consistent with the Code of Ethics for Pharmacists, which 
states “A pharmacist promotes the right of self-determination 
and recognizes individual self-worth by encouraging patients 
to participate in decisions about their health.”
4 
Through the provision of MTM services, pharmacists should 
promote the principle of autonomy.  In doing so, they 
encourage patients to make choices that align with their 
moral viewpoint and life plan.  For example, the medication 
therapy review “is designed to improve patients’ knowledge 
of their medications, address problems or concerns that 
patients may have, and empower patients to self-manage 
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their medications and their health conditions.”
 1
 This 
principles includes the obligation to resist or eliminate 
controlling influences (e.g. directive counseling) and promote 
autonomous decision-making by patients and guardians.
6
  
The later involves recognizing the worth of the patient and 
including his or her goals.  For example, patient beliefs and 
preferences should be taken into account when developing 
self-management goals related to health and well-being. 
 
It is of upmost importance to avoid actual or perceived 
coercive measures when promoting MTM services.  Patients 
should be made aware of any fees, including those related to 
the medication review, laboratory work, or immunizations, 
prior to agreeing to participate and receiving the service.  
Care should be taken to avoid implying false information. For 
example, it is inappropriate to suggest that the patient will 
have reduced health plan benefits if he chooses not to 
participate in a particular program, unless specific plan 
benefits exist. 
 
Pharmacists should assess medications for indication, 
efficacy, safety, and adherence during the MTM session.
7
 As 
medication experts, pharmacists need to provide education 
to patients and caregivers in a manner that supports patient 
decision-making and informed consent.  The information that 
is provided should be accurate, complete, and delivered in a 
way that each patient and/or caregiver can understand and 
act upon.  More than 1 in 3 adults in the United States have 
basic or below basic health literacy.
8
 Pharmacists should 
become familiar with signs of low health literacy and 
routinely incorporate plain language and the teach-back 
method when communicating with patients.
9,10
  MTM 
includes the assessment of not just literacy and education 
levels, but also cultural issues and language barriers that may 
inhibit comprehensive care.  Without taking the initiative to 
properly inform and educate, pharmacists are violating the 
principle of autonomy, and ultimately the dignity of each 
patient and caregiver. 
 
The principle of autonomy does not rest with patients and 
caregivers alone.  After assessing medications and discussing 
findings with the patient, the pharmacist must also 
communicate the information to other health care 
professionals so they too can make well-informed decisions 
and properly manage patient care.  Consider sharing with 
patients at the beginning of the visit how information will be 
communicated with other members of the health care team 
and third-parties, including if professional judgment 
determines that the patient or others are at risk.  If an 
established relationship between the MTM pharmacist and 
other health care professionals does not exist, it is important 
to ask patients how they would prefer to share non-urgent 
information with other members of their health care team.  
Some patients may prefer that the pharmacist reach out 
directly to their primary care provider (PCP), whereas others 
may prefer to have a personal discussion with their PCP.  
Pharmacists can support the latter preference by using 
patient friendly language to describe specific 
recommendations in the medication-related action plan.  
Multiple copies of the medication list and recommendations 
can be provided and patients can be encouraged to share and 
discuss the documents with their PCP. 
 
Veracity 
Related to the principle of autonomy is the principle of 
veracity, or truthfulness.  When informing and educating 
patients and caregivers, it is critical to provide truthful 
information even though such information may involve “bad 
news” or be perceived as harmful to the overall well-being of 
the patient.  It is important to establish a therapeutic 
relationship with patients to understand how information 
should be delivered as each patient may have different 
expectations.  In the Code of Ethics for Pharmacists, a 
pharmacist “has a duty to tell the truth and to act with 
conviction of conscience.”
4
 Furthermore, in being trusted by 
others, there is a dialectical relationship surrounding trust 
and honesty, “Considering the patient-pharmacist 
relationship as a covenant means that a pharmacist has moral 
obligations in response to the gift of trust received from 
society.  In return for this gift, a pharmacist promises to help 
individuals achieve optimum benefit from their medications, 
to be committed to their welfare, and to maintain their 
trust.”
4
 
 
Another aspect of veracity falls on the obligation of the 
pharmacist to represent his or her self accurately.  That is, if a 
pharmacist lacks a particular skill or falsifies or misrepresents 
an ability or skill, he or she violates the principle of veracity.  
In the Code of Ethics for Pharmacists, there are two specific 
areas that speak to the principle of veracity.  The first focuses 
on the guiding rule that a pharmacist maintains professional 
competency: “A pharmacist has a duty to maintain 
knowledge and abilities as new medications, devices, and 
technologies become available and as health information 
advances.”
4
  In order to provide optimal care, pharmacists 
providing MTM services must remain current in their 
knowledge of medications, disease states, and clinical 
guidelines.  Depending on the background and needs of the 
individual pharmacist, strategies to remain up-to-date may 
include seeking out continuing education that is beyond the 
minimum requirements set forth by the board of pharmacy 
or exploring opportunities to create a continuing professional 
development portfolio.
11,12
  Some pharmacists may find that 
completing residency training, fellowship training, or 
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certifications may help to demonstrate competency to 
patients, other health care professionals, and payors.
13
  
Furthermore, the pharmacy site may wish to apply for 
accreditation, such as through the Center for Pharmacy 
Practice Accreditation.
14
   
 
The second aspect of veracity focuses on the importance of 
collegial relationships, particularly when one may be limited 
in knowledge, skill, or resources: “When appropriate, a 
pharmacist asks for the consultation of colleagues or other 
health professionals or refers the patient.”
4
 This aligns with a 
core element of MTM, which includes referring patients to 
another health care professional when necessary.
1
 Without 
being guided by the principle of veracity, the pharmacist may 
lose credibility and respect among patients, colleagues, and 
other healthcare professionals, and dishonest acts may lead 
to avoidable harms.
 
 
Nonmaleficence  
Nonmaleficence, or “Primum non nocere” is the obligation to 
avoid or not inflict harm on others whether intentionally or 
unintentionally.
6
 Nonmaleficence expresses the limits of the 
principle of beneficence (discussed more thoroughly below), 
and reminds the pharmacist to consider the possible harms 
that may arise with any intervention.  The presence of harm 
should be avoided or prevented, however this principle also 
guides the pharmacist to evaluate the levels and types of 
harms present.  For example, if a pharmacist encounters a 
patient who is taking a harmful medication, the action that is 
guided by nonmaleficence is to stop the patient from taking 
the medication. Due to the patient-centered approach of 
MTM, the pharmacist’s observations and interpersonal 
patient care can lead to “early detection of medication-
related problems and thus have the potential to reduce 
inappropriate medication use, emergency department visits, 
and hospitalizations.”
 1
 
 
Organizations frequently develop policies and procedures to 
decrease medication errors during the medication dispensing 
process.
15,16
  Similarly, standardized policies and procedures 
for staff providing MTM services should be developed.  This 
should include steps to minimize distractions, which can lead 
to unintentional patient harm.  For example, a pharmacist 
who is interrupted while assessing a patient’s medications or 
documenting recommendations may miss important 
information.  If the pharmacist is interacting with a patient 
and is interrupted by another patient or staff member, the 
covenantal relationship between the patient and pharmacist 
may be disrupted.  This may result in the patient being less 
willing to share information, which may negatively impact 
patient care.  Developing strategies to avoid this problem 
may be particularly relevant in programs where one 
pharmacist is providing both dispensing and non-dispensing 
services concurrently.  Having standardized policies and 
procedures for staff also encourages consistency of care and 
creates expectations, both within the profession and with 
stakeholders (i.e., patients, other health care professionals, 
and payors) regarding appropriate levels of cognitive services 
by pharmacists.   
 
Comprehensive care should focus not only on disease 
management, but also health and wellness promotion.  
Pharmacists should be familiar with evidenced-based 
practices, such as U.S. Preventive Services Task Force 
(USPSTF) recommendations, related to indication for and 
frequency of screenings.
17
 Pharmacists may wish to utilize an 
electronic search tool of USPSTF recommendations to 
systematically assess wellness needs of each individual 
patient.
18,19
  Whenever possible, results from screenings 
should be shared with other members of the patient’s health 
care team to prevent duplication of testing.  This may result 
in unnecessary health care expenditures, as well as the 
probability of false-positive results requiring additional, often 
more invasive, testing. 
 
Additional considerations are warranted for programs that 
include potentially sensitive topics.  This could include HIV 
and genomics testing, as well as the emerging obligations of 
pharmacists to warn and protect third-parties (e.g., sexual 
partners, department of health, or CDC), when there is a 
potential harm to individuals or populations.
20,21
  Staff and 
pharmacists must understand legal obligations as well as 
present and future liabilities (e.g., access to genomic 
information).  It is important to incorporate processes to 
ensure patient privacy, both during the visit and related to 
data storage.  Furthermore, pharmacists should consider the 
possible psychological impact test results might have on 
patients and family members.  Training in the area of cultural 
competence is important as patients and families that receive 
care may have a variety of beliefs.
22
 It has been recognized 
that a lack of cultural competence can lead to poor health 
outcomes and health care disparities.
23
 Be sure to develop 
protocols for referring patients to other health care 
professionals for confirmation of test results, treatment, and 
counseling services.   
 
Beneficence 
The primary aim of MTM is to optimize therapeutic outcomes 
for individual patients, which is an example of beneficence, 
the obligation to act for the benefit of others.
1,2,6
  The 
principle of beneficence emphasizes the importance of 
weighing risks and benefits.  As Gert, Culver, and Clouser 
(1997) state, “As properly used in the biomedical ethics 
literature this principle is cited simply to give “validation” 
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both to preventing or relieving harm and to doing good or 
conferring benefits.”
24
 For example, a pharmacist providing a 
vaccine recognizes that there may be some harm involved 
when injecting a syringe (e.g., tenderness at the injection 
site), but that the overall benefits of being immunized from 
potentially harmful and/or transmittable diseases outweighs 
the discomfort of the injection.  Thus, beneficence prompts 
the pharmacist to weigh and balance possible benefits 
against existing or possible risks. 
 
Pharmacists should encourage patients to take an active role 
in developing health and wellness goals.  Example topics that 
may be addressed include medication adherence, disease 
self-management (e.g., blood glucose or blood pressure 
testing), healthy food choices, physical activity, and tobacco 
cessation.  Pharmacists can assess vaccine needs and, if 
permissible under state law, provide necessary 
immunizations during MTM sessions.
  
 Working 
collaboratively, patient and pharmacists can develop goals 
that are specific, measurable, attainable, realistic, and timely 
(SMART).
25 
These goals should be documented in the 
medication-related action plan if a comprehensive 
medication review is conducted.  This will provide an 
opportunity for the patient, in collaboration with the 
pharmacist, to assess progress, identify successes, and modify 
the goals as needed.  It may be beneficial to incorporate 
strategies, such as motivational interviewing, that emphasize 
the patient’s ability to make choices that align with their 
belief system.
26
   
 
Consider developing a list of local community resources.  
These might include support groups, parks and fitness 
centers, weight loss organizations, the public health 
department, agencies associated with aging, and the local 
library.  Some patients may bring up sensitive topics during 
the MTM session, particularly as they gain trust in their MTM 
pharmacist.  Contact information for child protective services, 
domestic violence shelters, food banks, and homeless 
shelters may be useful.  Finally, consider establishing policies 
to help patients who are at risk for or display warning signs of 
suicide. 
 
Justice 
The principle of justice is concerned with the fair distribution 
of benefits and burdens.
6
 Concerns of justice often arise 
when resources are scarce or inequality is present.  While 
there are various models of fair distribution to provide 
patients with resources or opportunities, the goal of these 
models is ultimately to protect vulnerable members of 
society and to minimize undue burdens, including the lack of 
available and accessible resources.  For example, with recent 
drug shortages, patients and providers may not have access 
to needed medications.  In such tragic events, the principle of 
justice can guide pharmacists to not only determine how 
limited resources should be distributed to those who are in 
need, but also to develop new solutions when there are no 
longer any resources to distribute, (e.g., deriving 
compounded medications from available drugs). 
 
Access to health services requires three steps: gaining entry 
into the health care system, accessing a location that 
provides the services, and finding a provider with whom the 
patient can communicate and trust.
27
 Decision-makers should 
develop policies and procedures that increase equitable 
access to care across all three domains, while addressing 
possible barriers and finding solutions. 
 
Patients may face a variety of challenges related to access of 
MTM services.  Patients may not be aware of the existing 
programs that are available in their communities.  Consider 
exploring if the patient population obtains health information 
from advertisements, community groups, news reports, social 
media, or other sources.  Identifying how to harness these 
methods of communication may lead to increased awareness 
of available services, which may result in improved 
participation among community members.    
 
Among patients with insurance coverage, inequities may exist 
related to accessing MTM services.  For example, racial and 
ethnic minorities may be less likely to meet MTM eligibility 
criteria.
28
 Out-of-pocket costs, particularly when there is a 
lack of insurance coverage for the MTM service, may be a 
barrier for some patients.  Furthermore, MTM programs may 
not be available within communities where patients reside.  If 
they are, patients may have difficulty accessing the location 
due to mobility or transportation barriers.  Alternative 
strategies, such as telephonic, electronic, or home visits 
should be explored to determine if rates of participation 
improve.  Additionally, pharmacists from diverse backgrounds 
should be encouraged to participate in the provision of MTM 
services.  Literature suggests that patients who share a 
common race, ethnicity, and language with their health care 
professional may have improved access to care, improved 
communication and relationships with the health care 
professional, and may be more likely to receive and accept 
appropriate medical care.
29 
 
Finally, MTM program should consider formally evaluating 
clinical, economic, and humanistic outcomes (ECHO) for the 
services provided to patients.
30
 Best practices should be 
disseminated so that effective strategies are integrated 
across programs.  Stakeholders, including heath insurance 
plans and patients, may look towards outcomes data to make 
decisions about the value of the services.  Demonstrating 
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value may lead to expanded services, as well as increased 
patient inclusion criteria.  Ultimately, these practices may 
result in improved patient and population health.   
 
Conclusion 
A growing number of pharmacists are providing MTM 
services.  Pharmacists and other champions of MTM should 
strive to incorporate strategies that lead to the promotion of 
the ethical principles of autonomy, veracity, nonmaleficence, 
beneficence, and justice, with the goal of improved patient 
and population health.  With a deeper understanding of 
ethical principles and the Code of Ethics for Pharmacists, 
pharmacists may be more prepared to make difficult ethical 
decisions, and ultimately, guide better patient care. 
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